Table 4 Univariate and multivariate analyses of the relationship of CD44⁺/CD24^-/low tumor cells to overall survival

From: CD44⁺/CD24^- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

Variable	Univariate analysis			Multivariate analysis
Variable	HR	95% CI	p-value	HR	95% CI	p-value
CD44⁺/CD24^-/low tumor cells
High	2.193	1.383-3.477	0.001	2.237	1.345-3.720	0.002
Low	1.000			1.000
ER status
Positive	0.757	0.488-1.175	0.215	1.164	0.585-2.314	0.665
Negative	1.000			1.000
PR status
Positive	0.702	0.457–1.078	0.106	0.968	0.496–1.888	0.924
Negative	1.000			1.000
Her2 status
Positive	0.932	0.605–1.435	0.748	1.583	0.782–3.201	0.201
Negative	1.000			1.000
Basal-like feature*
Present	0.608	0.389-0.949	0.029	0.342	0.131-0.891	0.028
Absent	1.000			1.000
TNM stage
Stage III/IV	1.614	1.055–2.470	0.027	1.652	1.014–2.690	0.044
Stage I/II	1.000			1.000
Lymph node involvement
Absent	0.891	0.528-1.504	0.666	0.674	0.343-1.323	0.251
Present	1.000			1.000
Age (years)
≥ 50	1.110	0.735–1.676	0.621	1.384	0.847–2.260	0.194
< 50	1.000			1.000

Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
^* Immunohistochemically negative for both SR and Her2.

Back to article page